Reason for request

Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code. Renewal of inclusion on the list of medicines refundable by National Health Insurance.


Clinical Benefit


The actual benefit of LEPONEX in the treatment of schizophrenia remains substantial.

The actual benefit of LEPONEX in this indication remains substantial.

Clinical Added Value


As a second-line therapy, LEPONEX provides a moderate improvement in actual benefit (IAB III) as regards its indication for the treatment of schizophrenia.

Contact Us

Évaluation des médicaments

See also